Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Bristol-Myers Squibb Acquires Celgene Corporation

January 4th 2019

Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement with Celgene Corporation under which BMS will acquire Celgene in a cash and stock transaction with an equity value of about $74 billion.

IMvoke010 Trial to Assess Adjuvant Atezolizumab in SCCHN

December 22nd 2018

An ongoing randomized phase III study will compare the safety and efficacy of atezolizumab with placebo as adjuvant therapy after definitive local therapy in patients with high-risk, locally advanced squamous cell carcinoma of the head and neck.

Robotic Surgical Approaches Advance Treatment in NSCLC

December 21st 2018

Robert J. Cerfolio, MD, discusses how the use of surgery has significantly evolved over the years and how advances made in robotic surgery improve quality of life of those who need to undergo these procedures.

Erdafitinib Shows Promise in FGFR-Aberrant Cholangiocarcinoma

December 20th 2018

Erdafitinib, an oral pan-FGFR inhibitor, demonstrated encouraging clinical activity and a manageable safety profile in Asian patients with FGFR-aberrant advanced cholangiocarcinoma.

Cemiplimab Combo Falls Short Versus Anti–PD-1 Monotherapy in HNSCC

December 19th 2018

The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and GM-CSF did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma.

De-Escalation Possible in Curative Setting for HER2+ Breast Cancer

December 18th 2018

Ciara O’Sullivan, MB, BCh, discusses the need for treatment de-escalation for patients with HER2-positive breast cancer, as well as the challenges that remain in tailoring treatment.

FDA Approves Trastuzumab Biosimilar for HER2+ Breast Cancer

December 17th 2018

The FDA has granted an approval to CT-P6, a trastuzumab biosimilar, for the treatment of patients with HER2-overexpressing breast cancer

Cemiplimab Antitumor Activity in CSCC Sustained With Longer Follow-up

December 17th 2018

The monoclonal anti-PD-1 antibody cemiplimab continued to demonstrate considerable antitumor activity and durable responses in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma.

Expert Addresses Controversies in Management of HR+ Early-Stage Breast Cancer

December 16th 2018

Rachel C. Jankowitz, MD, discusses the range of risk associated with HR-positive, HER2-negative breast cancer and the importance of communicating with patients about associated adverse events.

Expert Highlights Utility of PD-L1 to Select Immunotherapy in NSCLC

December 14th 2018

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Paradigm Evolving in HER2+ Breast Cancer With CNS Mets

December 11th 2018

Shannon L. Puhalla, MD, discusses some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.

CDK4/6 Inhibitors Are Transforming Treatment in HR+ Breast Cancer

December 11th 2018

Terry L. Evans, MD, discusses the impact of CDK4/6 inhibitors in the metastatic breast cancer space and challenges that still need to be addressed.

Neoadjuvant Immunotherapy Has Potential in Stage IIIa NSCLC

December 7th 2018

Nisha A. Mohindra, MD, discusses the current treatment landscape, challenges faced in this patient population, and what she believes will be a focus for further research over the next decade.

Axillary Radiotherapy Alternative to Lymph Node Dissection in Early-Stage Breast Cancer

December 7th 2018

Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.

Some Women May Benefit From Mammography Screening Beginning at Age 30

November 29th 2018

Women between the ages of 30 and 39 who have at least 1 of 3 risk factors may benefit from starting their annual mammography screening at age 30.

Novel Molecular Markers at Forefront of NSCLC Research

November 29th 2018

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

Immunotherapy Arrives in Stage III NSCLC, But Questions Remain

November 26th 2018

Thomas Hensing, MD, discusses the emergence of immunotherapy in the stage III non–small cell lung cancer armamentarium, and questions that must be answered to build on this initial success.

Brufsky Highlights Novel Approaches for TNBC

November 21st 2018

Adam M. Brufsky, MD, PhD, highlights novel treatment approaches being explored in the triple-negative breast cancer space.

Immunotherapy Combos Expand Across Lung Cancer Subtypes

November 21st 2018

Lawrence E. Feldman, MD, discusses exciting new data surrounding immunotherapy combinations in lung cancer.

EU Panel Backs Apalutamide in Nonmetastatic CRPC

November 19th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.